CYYNF (Cynata Therapeutics) Accounts Payable & Accrued Expense: $0.70 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cynata Therapeutics Accounts Payable & Accrued Expense?

Cynata Therapeutics CYYNF Accounts Payable & Accrued Expense is $0.70 Mil as of Jun. 2026. The stock has 1 warning sign investors should review.

Cynata Therapeutics's quarterly accounts payable & accrued expense declined from Jun. 2025 ($0.62 Mil) to Dec. 2025 ($0.57 Mil) but then increased from Dec. 2025 ($0.57 Mil) to Jun. 2026 ($0.70 Mil).

Cynata Therapeutics's annual accounts payable & accrued expense declined from Jun. 2024 ($0.63 Mil) to Jun. 2025 ($0.62 Mil) but then increased from Jun. 2025 ($0.62 Mil) to Jun. 2026 ($0.70 Mil).

Cynata Therapeutics Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Cynata Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cynata Therapeutics Accounts Payable & Accrued Expense Chart

Cynata Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 1.38 0.63 0.62 0.70

Cynata Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.71 0.62 0.57 0.70

Cynata Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $0.70 Mil mean?
Cynata Therapeutics (CYYNF) has a Accounts Payable & Accrued Expense of $0.70 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Cynata Therapeutics and its competitors.
Is Cynata Therapeutics' Accounts Payable & Accrued Expense too high?
Cynata Therapeutics' current Accounts Payable & Accrued Expense is $0.70 Mil.
How does Cynata Therapeutics' Accounts Payable & Accrued Expense compare to VRTX and REGN?
Cynata Therapeutics' Accounts Payable & Accrued Expense of $0.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Cynata Therapeutics and its competitors. Cynata Therapeutics's current Accounts Payable & Accrued Expense is $0.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current Accounts Payable & Accrued Expense of $0.70 Mil. The current Accounts Payable & Accrued Expense is $0.70 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current Accounts Payable & Accrued Expense is $0.70 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cynata Therapeutics Business Description

Other Exchanges 51S:GermanyCYP:Australia
Address 100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.